Budesonide: Teaching an old dog new tricks for inflammatory bowel disease treatment

Erika Angelucci, Alberto Malesci, Silvio Danese

Research output: Contribution to journalArticle

Abstract

Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative colitis, for the induction and maintenance of remission, respectively. The main limiting factors for the repeated use of corticosteroids or the use as a maintenance treatment are the very high prevalence of systemic side effects, together with the possibility of developing dependency on and/or resistance to the drug, which are reported in more than one third of patients with inflammatory bowel disease. In the last decade, a number of corticosteroids with enhanced topical activity and low systemic activity have been developed. Among them, budesonide and beclomethasone dipropionate are the most used for the treatment of the inflammatory bowel diseases. Indeed, budesonide is the drug of choice for the treatment of ileo(-cecal) active Crohn's disease with mild-to-moderate activity, due to controlled ileal release. Budesonide foam and/or enemas are also efficacious in the treatment of left-sided/distal ulcerative colitis. Gastroresistant, extended release tablets characterized by a multimatrix structure (i.e. MMX®-budesonide), have also been developed to allow uniform release along the length of the colon. This paper reviews the mechanism-of-action, safety and efficacy of budesonide in the treatment of inflammatory bowel disease.

Original languageEnglish
Pages (from-to)2527-2535
Number of pages9
JournalCurrent Medicinal Chemistry
Volume15
Issue number24
DOIs
Publication statusPublished - 2008

Fingerprint

Budesonide
Inflammatory Bowel Diseases
Teaching
Dogs
Ulcerative Colitis
Crohn Disease
Adrenal Cortex Hormones
Therapeutics
Beclomethasone
Remission Induction
Enema
Drug Resistance
Tablets
Colon
Pharmaceutical Preparations
Foams
Maintenance
Safety

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Budesonide : Teaching an old dog new tricks for inflammatory bowel disease treatment. / Angelucci, Erika; Malesci, Alberto; Danese, Silvio.

In: Current Medicinal Chemistry, Vol. 15, No. 24, 2008, p. 2527-2535.

Research output: Contribution to journalArticle

@article{580d826dab9d4fc39b01284accf5eea7,
title = "Budesonide: Teaching an old dog new tricks for inflammatory bowel disease treatment",
abstract = "Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative colitis, for the induction and maintenance of remission, respectively. The main limiting factors for the repeated use of corticosteroids or the use as a maintenance treatment are the very high prevalence of systemic side effects, together with the possibility of developing dependency on and/or resistance to the drug, which are reported in more than one third of patients with inflammatory bowel disease. In the last decade, a number of corticosteroids with enhanced topical activity and low systemic activity have been developed. Among them, budesonide and beclomethasone dipropionate are the most used for the treatment of the inflammatory bowel diseases. Indeed, budesonide is the drug of choice for the treatment of ileo(-cecal) active Crohn's disease with mild-to-moderate activity, due to controlled ileal release. Budesonide foam and/or enemas are also efficacious in the treatment of left-sided/distal ulcerative colitis. Gastroresistant, extended release tablets characterized by a multimatrix structure (i.e. MMX{\circledR}-budesonide), have also been developed to allow uniform release along the length of the colon. This paper reviews the mechanism-of-action, safety and efficacy of budesonide in the treatment of inflammatory bowel disease.",
author = "Erika Angelucci and Alberto Malesci and Silvio Danese",
year = "2008",
doi = "10.2174/092986708785909049",
language = "English",
volume = "15",
pages = "2527--2535",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "24",

}

TY - JOUR

T1 - Budesonide

T2 - Teaching an old dog new tricks for inflammatory bowel disease treatment

AU - Angelucci, Erika

AU - Malesci, Alberto

AU - Danese, Silvio

PY - 2008

Y1 - 2008

N2 - Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative colitis, for the induction and maintenance of remission, respectively. The main limiting factors for the repeated use of corticosteroids or the use as a maintenance treatment are the very high prevalence of systemic side effects, together with the possibility of developing dependency on and/or resistance to the drug, which are reported in more than one third of patients with inflammatory bowel disease. In the last decade, a number of corticosteroids with enhanced topical activity and low systemic activity have been developed. Among them, budesonide and beclomethasone dipropionate are the most used for the treatment of the inflammatory bowel diseases. Indeed, budesonide is the drug of choice for the treatment of ileo(-cecal) active Crohn's disease with mild-to-moderate activity, due to controlled ileal release. Budesonide foam and/or enemas are also efficacious in the treatment of left-sided/distal ulcerative colitis. Gastroresistant, extended release tablets characterized by a multimatrix structure (i.e. MMX®-budesonide), have also been developed to allow uniform release along the length of the colon. This paper reviews the mechanism-of-action, safety and efficacy of budesonide in the treatment of inflammatory bowel disease.

AB - Crohn's disease and ulcerative colitis are chronic relapsing inflammatory bowel diseases with extremely great variability in presentation and clinical course. For many decades, corticosteroids and aminosalicylates have been the mainstay of the treatment for both Crohn's disease and ulcerative colitis, for the induction and maintenance of remission, respectively. The main limiting factors for the repeated use of corticosteroids or the use as a maintenance treatment are the very high prevalence of systemic side effects, together with the possibility of developing dependency on and/or resistance to the drug, which are reported in more than one third of patients with inflammatory bowel disease. In the last decade, a number of corticosteroids with enhanced topical activity and low systemic activity have been developed. Among them, budesonide and beclomethasone dipropionate are the most used for the treatment of the inflammatory bowel diseases. Indeed, budesonide is the drug of choice for the treatment of ileo(-cecal) active Crohn's disease with mild-to-moderate activity, due to controlled ileal release. Budesonide foam and/or enemas are also efficacious in the treatment of left-sided/distal ulcerative colitis. Gastroresistant, extended release tablets characterized by a multimatrix structure (i.e. MMX®-budesonide), have also been developed to allow uniform release along the length of the colon. This paper reviews the mechanism-of-action, safety and efficacy of budesonide in the treatment of inflammatory bowel disease.

UR - http://www.scopus.com/inward/record.url?scp=55249114588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249114588&partnerID=8YFLogxK

U2 - 10.2174/092986708785909049

DO - 10.2174/092986708785909049

M3 - Article

C2 - 18855676

AN - SCOPUS:55249114588

VL - 15

SP - 2527

EP - 2535

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 24

ER -